Skip to main content
OpenTrials
Completed

NCT Number: NCT05819424

EpiCor Clinical Study on Rapid Immune Modulating Effects

Clinical verification study evaluating the effects of a nutraceutical product. This study involves thirty participants composed of healthy adults, who will be taking either a placebo or nutraceutical supplement at different times. Testing for immune status, cytokine levels, and immune responsiveness will be conducted to determine the acute impact of the nutraceutical on immune function compared to a placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NIS Labs

Klamath Falls, Oregon, 97601, United States

About this study

Clinical study comparing the acute immune effect of a nutraceutical product and a placebo. The nutraceutical supplement is a postbiotic whole food fermentate produced using yeast.

30 subjects will participate in a placebo-controlled, double-blind, randomized, cross-over design, wherein they will be taking a placebo, or nutraceutical product, each separated by a 1-week washout period to evaluate effects within 3 hours of consumption.

Blood samples will be taken 1 hour after participants arrive, then the dose is administered. Samples are taken 1 hour, 2 hours, and 3 hours following administration.

A series of immune panels will be used to determine the acute impacts on immune surveillance, immune cell activation status, and cytokine profiles. Ex vivo immune challenges will be used to determine the direct impacts on immune cells.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults of any gender
  • BMI between 18 and 30 (inclusive)
  • Veins easy to see in one or both arms (to allow for multiple blood draws)
  • Willing to comply with a 24-h wash-out period for vitamins and nutritional supplements
  • Willing to comply with study procedures including: maintaining a consistent diet and lifestyle routine throughout the study; consistent habit of bland breakfasts on days of clinic visits; abstaining from exercising and nutritional supplements on the morning of the study visit; abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit; abstaining from music, candy, bum, computer/cell phone use, during clinic visits.

Exclusion criteria

  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder)
  • Currently in intensive athletic training (such as marathon runners)
  • Currently taking antidepressant or tranquilizing medications
  • Taking anti-inflammatory medications on a daily basis
  • Currently experiencing intense stressful events/life changes that could negatively affect compliance
  • Anything that the investigator judges may put the subject at risk or may unduly influence any of the results of the study
  • An unusual sleep routine (examples: working nightshift, irregular routine with frequent late nights)
  • Unwilling to maintain a constant intake of supplements over the duration of the study
  • Anxiety about having blood drawn
  • People of childbearing potential: pregnant, nursing, or trying to become pregnant
  • Known food allergies related to ingredients in active test product or placebo

Prescription medication will be evaluated on case-by-case basis.

Treatment and study plan

Yeast Fermentate (EpiCor)

Dietary Supplement

Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.

Placebo: Substance with no therapeutic value to facilitate blinding

Primary outcomes

  1. Immune Surveillance

    Time frame: At 1, 2, and 3 hours

    Observation of changes in immune cell trafficking and status of immune cell alertness, i.e., the changes in immune cell populations and activation following administration

Secondary outcomes

  1. Immune Communication

    Time frame: At 1, 2, and 3 hours

    Serum cytokine levels as assessed by changes in cytokine levels individually versus placebo

Other outcomes

  1. Immune Responsiveness

    Time frame: At 1, 2, and 3 hours

    Ex vivo immune challenges, observing the capabilities of anti-bacterial and anti-viral defenses. Additionally, mucosal immune protection as determined by salivary IgA, defensins, and transferrin changes.

Sponsors and collaborators

Lead sponsor

Cargill

Industry

Collaborators

  • Natural Immune Systems Inc

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Apr 19, 2023
Registry last updated
Jan 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.